Boehringer Drug Cuts 16.6% Weight, FDA Seeks More Data
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Boehringer reported its obesity drug produced a 16.6% mean weight loss in early trials, but regulators say more data are required before approval.
- Novartis saw its shares dip in early trading after Q1 sales and operating profit fell, with generic competition eroding revenue from drugs like Entresto.
- Amgen had the FDA withdraw Tavneos from the market after the agency flagged untrue material statements in the approval filing, forcing a voluntary pullback.
- Eli Lilly struck a partnership with AI‑focused biotech Profluent to build gene‑editing platforms capable of inserting full genes into patients.
Why it matters: Boehringer and Eli Lilly stand to capture market share as their pipelines advance, while Novartis and Amgen face immediate revenue hits—Novartis shares slipped after a Q1 profit dip, Amgen must halt Tavneos sales—tightening investor confidence and prompting tighter regulatory scrutiny.
Ask SkimNews
